Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial

Por Samson, S. L., Sathyanarayana, P., Jogi, M., Gonzalez, E. V., Gutierrez, A., Krishnamurthy, R., Muthupillai, R., Chan, L., Bajaj, M.
Publicado em 2011

Increased abundance of the adaptor protein containing pleckstrin homology domain, phosphotyrosine binding domain and leucine zipper motif (APPL1) in patients with obesity and type...

Por Holmes, R. M., Yi, Z., De Filippis, E., Berria, R., Shahani, S., Sathyanarayana, P., Sherman, V., Fujiwara, K., Meyer, C., Christ-Roberts, C., Hwang, H., Finlayson, J., Dong, L. Q., Mandarino, L. J., Bajaj, M.
Publicado em 2011